Apr. 29, 2014
On April 29, 2014 Ambrx Inc. and Zhejiang-based Hisun Pharmaceutical announced a collaboration for the development and commercialization of bispecifics, which is based on Ambrx' technology for the treatment of cancer. Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun will manufacture the product according to cGMP standards for clinical and commercial supplies on a global basis.